Search Results

2022 08:00 AM Eastern Standard Time SAN FRANCISCO & SHANGHAI- ShouTi Inc., a clinical-stage global biopharmaceutical developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio

👉 In early-stage biotech , uncertainty is not an exception. It is the environment. Early-stage biotech hiring is not about perfect resumes. Why Skill-Based Hiring Breaks Down in Early-Stage Biotech Most early-stage biotech teams hire with good Early-stage biotech is none of those things. 👉 In early-stage biotech hiring, skills are selected based In early-stage biotech hiring, these moments arrive quietly.

👉 Biotech startups rarely fail all at once. This is one of the earliest reasons why biotech startups fail . This is a central reason why biotech startups fail . Order does not emerge naturally in biotech. Strategic Takeaway - Why biotech startups fail Biotech startups rarely fail because of a single mistake

Biotech fundraising has undergone a subtle yet significant shift. Clear intellectual property builds confidence on both sides of the biotech fundraising table Why biotech Biotech fundraising rarely fails in the diligence phase itself. In modern biotech fundraising, intellectual property functions as a shortcut. In biotech fundraising, coherence builds trust.

But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn Operating cadence is the quiet force behind biotech momentum, the rhythm that turns intention into real The Pattern: Your “Accidental Cadence” 👉 Every biotech has a cadence. Timeline slips are absorbed as “part of biology” rather than examined as managerial signals. Strategic Takeaway Your biotech is already running on an operating cadence.

The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where The Pattern: Scientific Isolation Scientific Isolation  = when a biotech’s internal activity becomes Alignment, structure, traction, visibility: these are the forces that pull a biotech out of scientific Most early biotechs think their problem is a lack of data. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not

For JB, that moment was a cold email from a biologist he’d never met, asking if he could synthesize a ask pulled a young chemist out of the fume hood and into the messy, electrifying world of live-cell biology Designing Reliable GPCR Imaging Tools for Real Biological Systems Success brought new challenges. Chemical probes may be elegant, but biology isn’t. Tissue is messy. David brought deep experience in islet biology, calcium imaging, and tissue physiology.

Most biotech pitches don’t fail because the science is weak. A clear biotech pitch answers three key questions immediately. Strong biotech pitches don’t just inform, they align. How to Fix the Gaps 👉 Fixing your biotech pitch doesn’t require a rebrand. A strong biotech pitch isn’t about saying more.

Every biotech founder fears the day the cash runs out. You track the burn rate. Example: You validate a biomarker for a broad indication. Most biotech founders don’t suffer from having the wrong people. A soft skill. ✅ But in biotech, alignment is a multiplier. It’s how biotech companies move from drift to direction.

It’s a pattern we see far too often in early-stage biotech operations and startups. The 3 Golden Rules of Scientific Thinking — and Why They Break Down in Biotech Operations Leadership   In startups, waiting too long for certainty can destroy your momentum . 👉 Biotech founders often delay Scientific thinking will always be your strength, but it must be reshaped to serve your new role. 👉 As a biotech Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

February 2022 "InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating to molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic need. 💊 InterAx Biotech AG discovery platform was already successfully applied in projects with biopharmaceutical companies #ai #biotech #systemsbiology #drugdiscovery #gpcr #deeptech #orphandrugs #pharma #partnerships #AI4drugdiscovery

July 2022 "G.CLIPS biotech is 2 years old today🎂. Looking forward for more 🎊 #team #grateful #biotech #work #birthdaycelebration" Read more at the source

The latest on how AI is being used to unlock elusive GPCR targets, financial results from Neurocrine Biosciences GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who discovery, pharmacology, antagonism, competitive, non-competitive, Terry's Corner, Yamina's Corner, biotech development, pharmaceutical, scientific career Hashtags: #DrGPCR #GPCR #DrugDiscovery #Pharmacology #Biotech

October 2022 "Enzymatic and cellular signalling biosensors are used to decipher the activities of complex biological systems. Biosensors for monitoring G protein-coupled receptors (GPCRs), the most drugged class of proteins in Here, we briefly summarize a subset of this field with accelerating importance: transducer biosensors

August 2022 A NanoBRET-Based H 3 R Conformational Biosensor to Study Real-Time H 3 Receptor Pharmacology in Cell Membranes and Living Cells "Conformational biosensors to monitor the activation state of G protein-coupled reported the initial characterization of a NanoBRET-based conformational histamine H3 receptor (H3R) biosensor In the current study, we have further characterized this H3R biosensor on intact cells by monitoring In addition, we have validated the H3R biosensor in membrane preparations and found that observed potency

August 2022 "Genetically encoded fluorescent biosensors allow intracellular signaling dynamics to be Many such biosensors are based on the principle of Förster resonance energy transfer (FRET), and we have recently developed a simple approach for in vivo detection of FRET-based biosensor signals using fiber By combining fiber photometry with FRET-based biosensors, we were able to track GPCR-dependent signaling This methodology would be compatible with other mammalian species and with many biosensors.

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical

December 2021 Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine Food and Drug Administration in 2022 SAN DIEGO, Dec. 7, 2021 /PRNewswire/ -- Neurocrine Biosciences (

that in connection with the Collaboration and License Agreement (“License Agreement”) with Neurocrine Biosciences (“Neurocrine Biosciences”) announced 22 November 2021, the applicable waiting period under the Hart-Scott-Rodino the applicable waiting period under the HSR Act, under the terms of the License Agreement Neurocrine Biosciences

January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special.

June 2022 Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adult (18 years of age and older) Patients with Classic CAH SAN DIEGO, June 13, 2022 -- Neurocrine Biosciences

that closed door lit the fuse for a career that would reimagine GPCR therapeutics — and lead to two biotech What followed was a scientific journey that now spans two biotech startups, and a bold reimagining of Clifford Woolf, a leader in pain biology. Launching Blue was Ajay’s first hands-on experience with biotech entrepreneurship. Lessons From the Front Lines of Biotech Ajay’s experience in both early-stage biotech and academic science

Drug discovery and development: Role of basic biological research. PLoS Biol. 2024;22(11):e3002870. 15.         Hunter P. Trends Biochem Sci. 2008;33(9):420-5. 20.         Nature chemical biology. 2020;16(8):841-849. 44.         J Biol Chem. 2018;293(19):7466-7473. 45.        

January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special.

Electron cryo-microscopy (cryo-EM) is a powerful technique for the structural characterization of biological Structural characterization of biologics, such as vaccines, viral vectors, and gene therapy agents, has

GPCRs Are Optimal Regulators of Complex Biological Systems and Orchestrate the Interface between Health physiological balance between healthy and pathological conditions; thus, their importance in systems biology

December 2022 Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Targets "Collaboration aims to combine Twist’s proprietary synthetic antibody libraries and sophisticated bioinformatics 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, and Twist Bioscience

November 2021 Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID --(BUSINESS WIRE)--Nov. 15, 2021-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers , Inc., an independently operated, new biotechnology company to develop and commercialize an antibody , discovered and optimized by Twist Biopharma, a division of Twist Bioscience, that neutralizes all known Revelar will have the ability to leverage the antibody discovery and optimization platform of Twist Biopharma

Significant advancements in the cellular biology of G protein-coupled receptors (GPCRs) about a novel biosensor shed light on the endosomal proteome associated with the δ-opioid receptor (DOR). This study, published in Nature Chemical Biology, highlights the role of the chaperone protein DNAJC13 How does this new biosensor work? APEX2 biosensor utilizes a fluorogenic substrate called Amplex UltraRed (AUR).

Through bioinformatic analysis of lysosomal proteomes, we identified lysosomal cholesterol signaling At high cholesterol concentrations, LYCHOS bound to the GATOR1 complex, a guanosine triphosphatase (GTPase By sequestering GATOR1, LYCHOS promotes cholesterol- and Rag-dependent recruitment of mTORC1 to lysosomes